China geographic atrophy market size and trajectory — the emerging commercial market for GA diagnosis and treatment reflecting both the enormous patient population and the recent therapeutic breakthrough creating the first-ever treatment options — represents a nascent but commercially significant market, with the China Geographic Atrophy Market reflecting the market's scale and...

Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) are rare, life-threatening disorders associated with dysregulation of the complement system. Increasing awareness of rare diseases, growing access to advanced diagnostic tools, and the development of targeted biologic therapies are significantly transforming the treatment landscape. Pharmaceutical companies...

The **Membranous Nephropathy Market** is currently in a phase of dynamic transformation, primarily fueled by substantial R&D investment directed towards novel therapeutic targets. Following the success of B-cell depletion with rituximab, the pharmaceutical pipeline is expanding to explore alternative mechanisms of action, particularly those targeting the complement pathway, T-cell...